Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - Company News (100 News)
Country: Germany · Primary market: Germany · EQS NID: 1841413
20 February 2024 08:37PM

CGM plans to double its dividend


EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Dividend
CGM plans to double its dividend

20.02.2024 / 20:37 CET/CEST
The issuer is solely responsible for the content of this announcement.


CGM plans to double its dividend

Koblenz. The general partner of CompuGroup Medical SE & Co. KGaA (CGM) intends to sustainably increase the dividend to a higher level, and will therefore propose a dividend of EUR 1.00 per share to the Annual General Meeting for the financial year 2023. Based on the 52.2 million shares currently entitled to a dividend payment, the planned total payout would double to EUR 52.2 million (previous year: EUR 26.1 million). Based on the year-end closing price for 2023 (Xetra closing price on December 29, 2023: EUR 37.90), this proposal corresponds to a dividend yield of 2.6 percent.

“The resilience of our business model and the improved free cash flow profile enable us to sustainably increase the dividend level for our shareholders while at the same time continuing to invest into future growth“, comments Michael Rauch, CEO of CompuGroup Medical.

The preliminary figures for the financial year 2023 and the guidance for 2024 were already announced on February 7, 2024. The full annual report will be published on the company's website under the Investor Relations section on March 28, 2024. Based on the final financial results for the financial year, the general partner and the supervisory board will decide on their final dividend proposal to the general meeting.

 



20.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1841413

 
End of News EQS News Service

1841413  20.02.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1841413&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.